Antimicrobials, vaccines, and anti-inflammatories are associated with a reduced risk for Alzheimer disease and dementia, while antipsychotics and drugs for diabetes are associated with an increased ...

With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been making waves in the healthcare sector with its groundbreaking treatments for ...

Whether you're curious to explore a healthy brain or brains affected by Alzheimer’s disease, vascular dementia, dementia with Lewy bodies, or Frontotemporal dementia, the choice is yours. Tailoring ...

These boards are cropping up around the US as neurologists acclimate to a new class of drugs, but not everyone agrees such ...

Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span ...

I’ve received texts from family members thanking me for what I’ve done,” volunteer Tom Kallas said. “It’s heartwarming to ...

Prolonged rapid eye movement (REM) sleep latency was linked with Alzheimer's disease biomarkers, cross-sectional data showed.

Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

A serial entrepreneur and a promising drug emerge from failed companies to pursue subsets of obesity patients, with or ...

On a quest to carve out a spot as one of the nuclear medicine greats, Massachusetts-based radiopharmaceutical specialist ...

Leerink Partners analyst David Risinger has reiterated their bullish stance on BMY stock, giving a Buy rating on January 12.Invest with ...